| Document Date: 2014-08-01 10:58:15
Open Document File Size: 921,08 KBShare Result on Facebook
Company Resverlogix Corp. / Citibank / Zenith Epigenetics Corp. / Resverlogix Inc. / RVX Therapeutics Inc. / / Country United States / Canada / / Currency USD / CAD / / Event M&A / Debt Financing / Patent Issuance / Funding / General or Shareholder Meeting / Reorganization / Business Partnership / Dividend Issuance / Company Expansion / Second Stock Issuance / / IndustryTerm business development services / pharmaceutical agent / insurance charges / manufacturing / site management / / MedicalCondition disease / percent atheroma volume / cardiovascular disease / coronary atherosclerosis / atheroma / diseases / / Organization Alberta Securities Commission / ded / / Person Adverse Cardiac / / Position investigator / director / Major / General and Administrative General / Private / / Product Crestor / Lipitor / RVX-208 / / ProvinceOrState Alberta / / Technology pharmacokinetics / drug metabolism / gene expression / ATM / 208 technology / drug development / CAD / /
SocialTag |
MANAGEMENT’S DISCUSSION & ANALYSIS – Fiscal[removed]April 30, 2014) This Management’s Discussion and Analysis (“MD&A”) of Resverlogix Corp.’s operations and financial position should be read in conjunction with